EP1578945A4 - Cct6s als modifikatoren des rb-wegssowie verwendungsverfahren - Google Patents

Cct6s als modifikatoren des rb-wegssowie verwendungsverfahren

Info

Publication number
EP1578945A4
EP1578945A4 EP03789986A EP03789986A EP1578945A4 EP 1578945 A4 EP1578945 A4 EP 1578945A4 EP 03789986 A EP03789986 A EP 03789986A EP 03789986 A EP03789986 A EP 03789986A EP 1578945 A4 EP1578945 A4 EP 1578945A4
Authority
EP
European Patent Office
Prior art keywords
cct6
modifiers
pathway
corresponding methods
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03789986A
Other languages
English (en)
French (fr)
Other versions
EP1578945A3 (de
EP1578945A2 (de
Inventor
Albert K Tai
Chunyan Song
Michael Martin Ollmann
Lucile A Gillett
Kim Lickteig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of EP1578945A3 publication Critical patent/EP1578945A3/de
Publication of EP1578945A2 publication Critical patent/EP1578945A2/de
Publication of EP1578945A4 publication Critical patent/EP1578945A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP03789986A 2002-11-25 2003-11-24 Cct6s als modifikatoren des rb-wegssowie verwendungsverfahren Withdrawn EP1578945A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42887202P 2002-11-25 2002-11-25
US428872P 2002-11-25
PCT/US2003/037548 WO2004048541A2 (en) 2002-11-25 2003-11-24 Cct6s as modifiers of the rb pathway and methods of use

Publications (3)

Publication Number Publication Date
EP1578945A3 EP1578945A3 (de) 2005-08-18
EP1578945A2 EP1578945A2 (de) 2005-09-28
EP1578945A4 true EP1578945A4 (de) 2006-09-27

Family

ID=32393472

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03789986A Withdrawn EP1578945A4 (de) 2002-11-25 2003-11-24 Cct6s als modifikatoren des rb-wegssowie verwendungsverfahren

Country Status (5)

Country Link
EP (1) EP1578945A4 (de)
JP (1) JP4646631B2 (de)
AU (2) AU2003294501B2 (de)
CA (1) CA2506686A1 (de)
WO (2) WO2004048541A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2798956A1 (de) 2007-04-23 2014-11-05 Stowers Institute for Medical Research Verfahren und Zusammensetzungen für die Selbsterneuerung von haematopoetischen Stammzellen

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041433A1 (en) * 1996-04-29 1997-11-06 Cancer Research Campaign Technology Limited METHOD AND MEANS FOR DISRUPTION OF p53 AND RB INTERACTION
WO1999041376A2 (en) * 1998-02-12 1999-08-19 Curagen Corporation Retinoblastoma protein complexes and retinoblastoma interacting proteins
US6071715A (en) * 1993-08-12 2000-06-06 Board Of Regents, The University Of Texas System Nucleic acids encoding novel proteins which bind to retinoblastoma protein

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071715A (en) * 1993-08-12 2000-06-06 Board Of Regents, The University Of Texas System Nucleic acids encoding novel proteins which bind to retinoblastoma protein
WO1997041433A1 (en) * 1996-04-29 1997-11-06 Cancer Research Campaign Technology Limited METHOD AND MEANS FOR DISRUPTION OF p53 AND RB INTERACTION
WO1999041376A2 (en) * 1998-02-12 1999-08-19 Curagen Corporation Retinoblastoma protein complexes and retinoblastoma interacting proteins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DECAPRIO ET AL: "The Product of the Retinoblastoma Susceptibility Gene Has Properties of a Cell Cycle Regulatory Element", CELL, vol. 58, pages 1085 - 1095, XP008087857 *
FELDMAN DOUGLAS E ET AL: "Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC", MOLECULAR CELL, vol. 4, no. 6, December 1999 (1999-12-01), pages 1051 - 1061, XP002394305, ISSN: 1097-2765 *
KUBOTA HIROSHI ET AL: "Structures and co-regulated expression of the genes encoding mouse cytosolic chaperonin CCT subunits", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 262, no. 2, June 1999 (1999-06-01), pages 492 - 500, XP002394304, ISSN: 0014-2956 *
LI WEN-ZHUO ET AL: "Tcp20, a subunit of the eukaryotic TRiC chaperonin from humans and yeast", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 28, 1994, pages 18616 - 18622, XP002394303, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
AU2003294499A1 (en) 2004-06-18
WO2004048536A3 (en) 2004-08-19
AU2003294501A1 (en) 2004-06-18
AU2003294499A8 (en) 2004-06-18
WO2004048541A3 (en) 2005-08-18
CA2506686A1 (en) 2004-06-10
JP4646631B2 (ja) 2011-03-09
AU2003294501B2 (en) 2010-05-13
WO2004048536A2 (en) 2004-06-10
EP1578945A2 (de) 2005-09-28
WO2004048541A2 (en) 2004-06-10
JP2006507005A (ja) 2006-03-02

Similar Documents

Publication Publication Date Title
EP1401475A4 (de) Prmts als modifikatoren des p53-pfads und anwendungsverfahren
EP1660638A4 (de) Lipopartikel umfassende proteine, verfahren zur herstellung und verwendung davon
EP1804675A4 (de) Verbesserter kombinierter sensor-führungsdraht und anwendungsverfahren
EP1601760A4 (de) Nanoporen, verfahren zu deren verwendung, verfahren zu deren herstellung und verfahren zur charakterisierung von biomolekülen unter verwendung davon
FR12C0019I2 (fr) O-cyclopropyle-carboxanilides et leur utilisation comme fongicides
EP1474687A4 (de) Marks als modifikatoren des p53-pfades und anwendungsverfahren
EP1495161A4 (de) Elektropolier- und galvanisierverfahren
EP1476150A4 (de) Carboxyfullerene und verwendungsverfahren dafür
EP1421384A4 (de) Hprp4s als modifikatoren des p53-wegs sowie verwendungsverfahren
DE50311735D1 (de) Das tissue engineering von knochen
EP1863769A4 (de) Hsp90-inhibitoren, verfahren zu deren herstellung und deren anwendungen
EP1402051A4 (de) Lces als modifikatoren des p53-wegs und verwendungsverfahren
EP1663249A4 (de) 1,3-diacylierte,26,27-alkyl/haloalkyl vitamin d sb 3 /sb verbindungen und anwendungsverfahren dafür
EP1587485A4 (de) Ölaufsaugende topische zusammensetzungen und anwendungsverfahren dafür
EP1412746A4 (de) HADHs ALS MODIFIKATOREN DES P21-WEGS UND VERWENDUNGSVERFAHREN
EP1651956A4 (de) Melks als modifikatoren des rac-wegs und verwendungsverfahren
EP1405074A4 (de) P5CRS ALS MODIFIKATOREN DES p53-WEGS UND VERWENDUNGSVERFAHREN
EP1453532A4 (de) Taojiks als modifikatoren des beta-catenin-pfads und anwendungsverfahren
EP1535067A4 (de) Papsss als modifikatoren des axin-wegs und verwendungsverfahren
EP1662209A4 (de) Feuchtigkeitskonditioniervorrichtung
EP1623018A4 (de) Mptene als modifikatoren des pten/igf-wegs und verwendungsverfahren
EP1578934A4 (de) FLJ20647s ALS MODIFIKATOREN DES p21-WEGS UND VERWENDUNGSVERFAHREN
EP1540333A4 (de) Maxs als modifizierer des axin-weges und verfahren zur verwendung
EP1687405A4 (de) Ttbks als modifikatoren des beta-catenin-wegs sowie verwendungsverfahren
EP1539990A4 (de) PSMCs ALS MODIFIKATOREN DES RB-WEGS UND VERWENDUNGSVERFAHREN

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

17P Request for examination filed

Effective date: 20050511

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 01N 61/00 B

Ipc: 7C 12Q 1/68 B

Ipc: 7G 01N 33/53 B

Ipc: 7G 01N 33/48 A

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 49/00 20060101ALI20060817BHEP

Ipc: C12Q 1/00 20060101AFI20060817BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20060830

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LICKTEIG, KIM

Inventor name: GILLETT, LUCILE, A.

Inventor name: OLLMANN, MICHAEL, MARTIN

Inventor name: SONG, CHUNYAN

Inventor name: TAI, ALBERT, K.

17Q First examination report despatched

Effective date: 20070301

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120601